Ganfort/Ganfort PF

Ganfort/Ganfort PF

bimatoprost + timolol




Concise Prescribing Info
Per mL Timolol 5 mg, bimatoprost 0.3 mg
Reduction of IOP in open-angle glaucoma or ocular HTN insufficiently responsive to topical β-blockers or prostaglandin analogues.
Dosage/Direction for Use
Ganfort Adult & elderly 1 drop in the affected eye(s) once daily in the morning. Ganfort PF 1 drop in the affected eye(s) once daily in the morning or evening at the same time each day.
Hypersensitivity. Bronchial asthma, severe COPD, sinus bradycardia, 2nd-or 3rd-degree AV block, overt cardiac failure, cardiogenic shock. Ganfort PF History of bronchial asthma; sinus bradycardia, sick sinus syndrome, sino-atrial nodal block.
Special Precautions
Renal or hepatic impairment. Pregnancy & lactation. Childn or adolescent. Ganfort Adequate control of cardiac failure before starting therapy. History of severe cardiac disease. Asthma, hyperthyroidism, Prinzmetal's angina, severe peripheral & central circulatory disorders, hypotension, diabetes. Patients w/ known risk factors for macular oedema. Remove contact lenses prior to application & reinsert ≥15 min after. Patients w/ dry eyes where the cornea is compromised. Ganfort PF Active intraocular inflammation (eg, uveitis). Aphakic patients, pseudophakic patients w/ torn posterior lens capsule or w/ known risk factors for macular edema (eg, intraocular surgery, retinal vein occlusions, ocular inflammatory disease & diabetic retinopathy). Potential permanent increased brown iris pigmentation, & hair growth may occur in skin areas w/ Ganfort PF contact. Monitor for IOP changes. Patients w/ inflammatory ocular conditions, neovascular glaucoma, inflammatory glaucoma, angle-closure glaucoma, congenital or narrow-angle glaucoma. Preexisting or history of CV disease (eg, CHD, Prinzmetal's angina & cardiac failure) & hypotension. 1st degree heart block. Severe peripheral circulatory disturbance/disorders (ie, Raynaud's phenomenon). Mild or moderate COPD. History of atopy or severe anaphylactic reactions. Diabetics (especially those w/ labile diabetes). May mask signs of hyperthyroidism & hypoglycemia. Corneal disease. Choroidal detachment may occur. Concomitant use w/ other β-blocking agents & surgical anesth. Remove contact lenses prior to administration & reinsert at least 15 min after instillation. May have negligible influence on the ability to drive or use machines.
Adverse Reactions
Conjunctival hyperemia, growth of eyelashes, superficial punctate keratitis, eye pruritus, foreign body sensation in the eyes, eye dryness, eyelid erythema, photophobia. Ganfort Corneal erosion, burning sensation, stinging sensation in the eye, eyelid pain/discharge/pruritus, blepharal pigmentation. Ganfort PF Eye irritation, increased lacrimation, conjunctival irritation; headache; skin (periocular) hyperpigmentation. Eyelid pruritus, abnormal sensation in eye, eyelash discoloration, eyelid edema, asthenopia, fatigue.
Drug Interactions
Potential additive effects w/ systemic β-adrenergic blocking agents. Hypotension/bradycardia w/ Ca channel blockers (oral), anti-arrhythmics (including amiodarone, digitalis glycosides, parasympathomimetics, guanethidine & other antihypertensives. Mydriasis may occur w/ adrenaline. Potentiated systemic β-blockade w/ CYP2D6 inhibitors.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
Ganfort: E-D; Ganfort PF: S
Ganfort eye drops
3 mL x 1's
Ganfort PF eye drops
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in